Evaluating early administration of the hydroxymethylglutaryl-CoA reductase inhibitor simvastatin in the prevention and treatment of delirium in critically ill ventilated patients (MoDUS trial): Study protocol for a randomized controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  Casarin, Annalisa ^a   McAuley, Daniel F ^b,c   Alce, Timothy M ^d   Zhao, Xiaobei ^a   Ely, E Xiaobei ^e,f   Jackson, Jim C ^e,g   McDowell, Cliona ^c   Agus, Ashley ^c   Murphy, Lynn ^c   Page, Valerie J ^a,h  

^a WATFORD GENERAL HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

^d NEVILL HALL HOSPITAL   (United Kingdom)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Beta amyloid; Cognitive impairment; Delirium prevention; Statins

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CHOLINESTERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN; ACETYLCHOLINESTERASE; ANTIINFLAMMATORY AGENT; AUTACOID; NEUROPROTECTIVE AGENT;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BIOLOGICAL ACTIVITY; BLOOD ANALYSIS; CLINICAL EVALUATION; COGNITIVE DEFECT; COMA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CRITICALLY ILL PATIENT; DELIRIUM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EARLY INTERVENTION; ECONOMIC EVALUATION; ENZYME ACTIVITY; FOLLOW UP; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INCIDENCE; INFLAMMATION; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME; URINALYSIS; VENTILATED PATIENT; ADVERSE EFFECTS; BLOOD; CLINICAL PROTOCOL; COGNITION; CRITICAL ILLNESS; DRUG ADMINISTRATION ROUTE; DRUG EFFECTS; ENGLAND; HOSPITAL MORTALITY; METHODOLOGY; PSYCHOLOGY; RISK FACTOR; TIME FACTOR;

ACETYLCHOLINESTERASE; AMYLOID BETA-PEPTIDES; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; BUTYRYLCHOLINESTERASE; CLINICAL PROTOCOLS; COGNITION; CRITICAL ILLNESS; DELIRIUM; DRUG ADMINISTRATION ROUTES; ENGLAND; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTENSIVE CARE UNITS; LENGTH OF STAY; NEUROPROTECTIVE AGENTS; RESEARCH DESIGN; RESPIRATION, ARTIFICIAL; RISK FACTORS; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929414487     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-0731-0     Document Type: Article

References (35)

1. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291(14):1753-62.
2. Xie Z, Dong Y, Maeda U, Moir R, Inouye SK, Culley DJ, et al. Isoflurane-induced apoptosis: a potential pathogenic link between delirium and dementia. J Gerontol. 2006;61A:1300-6.
3. Simone MJ, Tan ZS. The role of inflammation in the pathogenesis of delirium and dementia in older adults: a review. CNS Neurosci Ther. 2011;17:506-13.
4. Cunningham C. Systemic inflammation and delirium: important co-factors in the progression of dementia. Biochem Soc Trans. 2011;39:945-53.
5. Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, et al. Long-term cognitive impairment after critical illness. N Engl J Med. 2013;369(14):1306-16.
6. Milbrandt EB, Deppen S, Harrison PL, Shintani AK, Speroff T, Stiles RA, et al. Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 2004;32(4):955-62.
7. Girard TD, Jackson JC, Pandharipande PP, Pun BT, Thompson JL, Shintani AK, et al. Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. Crit Care Med. 2010;38:1513-191.
8. Mac Sweeney R, Barber V, Page V, Ely EW, Perkins GD, Young JD, et al. A national survey of the management of delirium in UK intensive care units. QJM. 2010;103(4):243-51.
9. Page VJ, Ely EW, Gates S, Zhao XB, Alce T, Shintani AK, et al. Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2013;1(7):515-23.
10. Girard TD, Pandharipande PP, Carson SS, Schmidt GA, Wright PE, Canonico AE, et al. Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomised, placebo-controlled trial. Crit Care Med. 2010;38:428-37.
11. Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA, Burgos JS. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis. 2011;23(2):307-18.
12. Cunningham C, Campion S, Lunnon K, Murray CL, Woods JF, Deacon RM, et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry. 2009;65:304-12.
13. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64(3):354-62.
14. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11:32.
15. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002;166(10):1338-44.
16. Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001;29(7):1370-9.
17. Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B, et al. Sedation Practice in Intensive Care Evaluation (SPICE) Study Investigators; ANZICS Clinical Trials Group. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. Am J Respir Crit Care Med. 2012;186(8):724-31.
18. Tun P, Lachman M. Telephone assessment of cognitive function in adulthood: the Brief Test of Adult Cognition by Telephone. Age Ageing. 2006;35:629-32.
19. Jorm A. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): a review. Int Psychogeriatr. 2004;16:1-19.
20. Graff-Radford N, Crook J, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma Aß42/Aß40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer's Disease. Arch Neurol. 2007;64:354-62.
21. Yaffe K, Weston A, Graff-Radford N, Satterfield S, Simonsick EM, Younkin SG, et al. Association of plasma ß-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA. 2011;305:261-6.
22. Cerejeira J, Nogueira V, Luis P, Vaz-Serra A, Mukaetova-Ladinska E. The cholinergic system and inflammation: common pathways in delirium pathophysiology. J Am Geriatr Soc. 2012;60:669-75.
23. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5 L). Qual Life Res. 2011;20(10):1727-36.
24. Girard TD, Kress JP, Fuchs BD, Thomason JW, Schweickert WD, Pun BT, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet. 2008;371(9607):126-34.
25. Van den Boogaard M, Pickkers P, Slooter AJ, Kuiper MA, Spronk PE, van der Voort PH, et al. Development and validation of PRE-DELIRIC (PREdiction of DELIRium in ICU patients) delirium prediction model for intensive care patients: observational multicentre study. BMJ. 2012;9(344), e420.
26. Executive NHS. National schedule of reference costs 2010/11. London: Department of Health; 2011.
27. Curtis L. Unit costs of health and social care. Canterbury: University of Kent, Personal Social Services Research Unit; 2011.
28. Morandi A, Hughes CG, Thompson JL, Pandharipande PP, Shintani AK, Vasilevskis EE, et al. Statins and delirium during critical illness: a multicenter, prospective cohort study. Crit Care Med. 2014;42:1899-909.
29. Page VJ, Davis D, Zhao XB, Norton S, Casarin A, Brown T, et al. Statin use and risk of delirium in the critically ill. Am J Respir Crit Care Med. 2014;189:666-73.
30. Li JJ, Wang Y, Nie SP, Zhang CY, Li YS, Hui RT, et al. Reduction of C-reactive protein by a single 80 mg of simvastatin in patients with unstable angina. Clin Chim Acta. 2007;376:163-7.
31. Shyamsundar M, McKeown ST, O'Kane CM, Craig TR, Brown V, Thickett DR, et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med. 2009;179(12):1107-14.
32. Ostadal P, Alan D, Hajek P, Horak D, Vejvoda J, Trefanec J, et al. The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. Mol Cell Biochem. 2003;246(1-2):45-50.
33. Shah AI, Sobnosky S, Shen AY, Jorgensen MB. High dose statins are associated with a reduced all cause mortality in patients hospitalized with sepsis and severe sepsis. Crit Care Med. 2009;36:A15.
34. Al Harbi SA, Tamin HN, Arabi YM. Association between statin therapy and outcomes in critically ill patients: a nested cohort study. BMC Clin Pharmacol. 2011;11:12.
35. Craig TR, Duffy MJ, Shyamsundar M, McDowel C, O'Kane CMJ, Elborn S, et al. A randomized clinical trial of hydroxymethylglutaryl-coenzyme A reductase inhibition for acute lung injury (the HARP study). Am J Respir Crit Care Med. 2011;183:620-6.